ATE160361T1 - Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose - Google Patents

Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose

Info

Publication number
ATE160361T1
ATE160361T1 AT88900775T AT88900775T ATE160361T1 AT E160361 T1 ATE160361 T1 AT E160361T1 AT 88900775 T AT88900775 T AT 88900775T AT 88900775 T AT88900775 T AT 88900775T AT E160361 T1 ATE160361 T1 AT E160361T1
Authority
AT
Austria
Prior art keywords
diagnosis
therapy
epithelial mucin
mucin polypeptides
human
Prior art date
Application number
AT88900775T
Other languages
English (en)
Inventor
Joyce Taylor-Papadimitriou
Sandra Gendler
Joy Burchell
Original Assignee
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878700269A external-priority patent/GB8700269D0/en
Priority claimed from GB878700279A external-priority patent/GB8700279D0/en
Priority claimed from GB878726172A external-priority patent/GB8726172D0/en
Application filed by Imp Cancer Res Tech filed Critical Imp Cancer Res Tech
Application granted granted Critical
Publication of ATE160361T1 publication Critical patent/ATE160361T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT88900775T 1987-01-07 1988-01-07 Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose ATE160361T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878700269A GB8700269D0 (en) 1987-01-07 1987-01-07 Probe
GB878700279A GB8700279D0 (en) 1987-01-07 1987-01-07 Probe
US4130687A 1987-04-22 1987-04-22
GB878726172A GB8726172D0 (en) 1987-11-09 1987-11-09 Probe

Publications (1)

Publication Number Publication Date
ATE160361T1 true ATE160361T1 (de) 1997-12-15

Family

ID=27449866

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88900775T ATE160361T1 (de) 1987-01-07 1988-01-07 Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose

Country Status (7)

Country Link
EP (3) EP0341252B1 (de)
JP (3) JPH02501828A (de)
AT (1) ATE160361T1 (de)
AU (1) AU1103988A (de)
CA (1) CA1339204C (de)
DE (1) DE3856072T2 (de)
WO (1) WO1988005054A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222509A (en) † 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
CA2003211A1 (en) * 1988-11-17 1990-05-17 Pei-Xiang Xing Monoclonal antibodies
JPH02255097A (ja) * 1989-03-29 1990-10-15 Ikuo Yamashina 単クローン抗体ｎｎｙ１２８
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
CA2040513A1 (en) * 1990-04-16 1991-10-17 Robert C. Bast, Jr. Method of diagnosing cancer
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
AU685539B2 (en) * 1993-12-24 1998-01-22 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Antigen carbohydrate compounds and their use in immunotherapy
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
EP0964694A4 (de) * 1996-10-25 2000-09-13 Dana Farber Cancer Inst Inc Mucin-vermittelte immunomodulation
US7550146B2 (en) 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
WO1998046246A1 (en) 1997-04-16 1998-10-22 Sloan-Kettering Institute For Cancer Research α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
GB9717946D0 (en) * 1997-08-22 1997-10-29 Imp Cancer Res Tech Novel chemical entity
DE19758400A1 (de) 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
JP5111705B2 (ja) 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
SI2266603T1 (sl) 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumorska cepiva
EP1531842A4 (de) 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation des zellwachstums durch muc1
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
EP1965190A1 (de) * 2007-02-27 2008-09-03 Qiagen GmbH Fixierung einer biologischen Probe
JP5331105B2 (ja) 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
BR112012028893A2 (pt) 2010-05-10 2017-12-12 Ascend Biopharmaceuticals Pty Ltd composições imunoestimuladoras e de vacina
JP5490901B2 (ja) 2010-08-06 2014-05-14 Ｙｋｋ株式会社 生地評価装置
CA2938819A1 (en) 2014-02-06 2015-08-13 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Antibody to mucin 4 (muc4) glycopeptide and uses thereof
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
JP2024503933A (ja) 2021-01-27 2024-01-29 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｃｄ１６ａに対する単一ドメイン抗体およびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
CA2003211A1 (en) * 1988-11-17 1990-05-17 Pei-Xiang Xing Monoclonal antibodies

Also Published As

Publication number Publication date
JPH10276773A (ja) 1998-10-20
EP1103623A1 (de) 2001-05-30
CA1339204C (en) 1997-08-05
EP0341252A1 (de) 1989-11-15
DE3856072D1 (de) 1998-01-02
DE3856072T2 (de) 1998-03-12
WO1988005054A1 (en) 1988-07-14
EP0823438A2 (de) 1998-02-11
JPH02501828A (ja) 1990-06-21
AU1103988A (en) 1988-07-27
JP2000333675A (ja) 2000-12-05
EP0341252B1 (de) 1997-11-19
EP0823438A3 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
ATE160361T1 (de) Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
DE3886060D1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins.
ATE315654T1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
EP0375724A4 (en) Biologically active bactericidal/permeability-increasing protein fragments
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
DK597288D0 (da) Rekombinant, humant immunoglobulin og fremgangsmaade til fremstilling deraf
UA39161C2 (uk) Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують
NO885326D0 (no) Human vevfaktor-beslektede dna-segmenter, polypeptider og antistoffer.
DE69838888D1 (de) Menschliche Toll-Homologe
ZA891861B (en) Monoclonal antibodies
IL88293A0 (en) Alveolar surfactant proteins
DK156592D0 (da) Human-h1-praeprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet og fremgangsmaade til sammenfoejning af a- og b-kaederne i human-h1-relaxin
EP0538401A4 (en) Novel receptor-type phosphotyrosine phosphatase
EP0398955A4 (en) Diagnosis of retinoblastoma
DE69729954D1 (de) Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden
DE3482840D1 (de) Expressionsvektoren und deren verwendung zur herstellung eines proteins mit menschlicher alpha-antitrypsin-aktivitaet.
DE3879085D1 (de) Snrnp-a-antigen und fragmente davon.
DE69940927D1 (de) PEPTIDFRAGMENTE MIT DEN ZELLTOD VERHINDERNDEr AKTIVITÄT
DE3887053D1 (de) Stlv-iii-verwandte polypeptide, diagnosesysteme und testmethoden.
FI894852A7 (fi) Menetelmä ihmisten ja eläinten kehonnesteiden tutkimiseksi sekä reagen ssi tätä varten
DE3886032D1 (de) Hiv-1-verwandte polypeptide, diagnosesysteme und testverfahren.
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.
ATE100110T1 (de) Stlv-iii-verwandte polypeptide, diagnosesysteme und testmethoden.
MY126634A (en) A novel polypeptide hormone phosphatonin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time